|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Restructuring charges | ||
| Total operating expenses | ||
| Loss from operations | ||
| Change in fair value of derivative tranche liability | ||
| Interest income | ||
| Other income (expense), net | ||
| Net loss | ||
| Other comprehensive loss | ||
| Unrealized gain (loss) on short-term marketable securities, net | ||
| Unrealized (loss) gain on short-term marketable securities, net | ||
| Total other comprehensive (loss) gain | ||
| Net loss and other comprehensive loss | ||
| Net loss per share attributable to common stockholder, basic (in shares) | ||
| Net loss per share attributable to common stockholder, diluted (in shares) | ||
| Weighted-average common shares outstanding, basic (in shares) | ||
| Weighted-average common shares outstanding, diluted (in shares) |
Loading...
